Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse tra...
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study of Efavirenz in Combination With Stavudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002225
- Locations
- 🇺🇸
Univ of Rochester Med Ctr, Rochester, New York, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸North Shore AIDS Hosp / Division of Infectious Disease, Manhassett, New York, United States
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00002386
- Locations
- 🇺🇸
Riley Hosp for Children, Indianapolis, Indiana, United States
🇺🇸Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT00002096
- Locations
- 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Ctr for Special Immunology, Irvine, California, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002001
- Locations
- 🇵🇷
San Juan Veterans Administration Med Ctr, San Juan, Puerto Rico
🇺🇸Georgetown Univ Med Ctr / Main Hosp 4, Washington, District of Columbia, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00000652
- Locations
- 🇺🇸
Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 1125
- Registration Number
- NCT00013520
- Locations
- 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Northwestern University CRS, Chicago, Illinois, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, St. Louis, Missouri, United States
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 300
- Registration Number
- NCT00000918
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-04-30
- Target Recruit Count
- 10
- Registration Number
- NCT00001035
- Locations
- 🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸USC CRS, Los Angeles, California, United States
Evaluation of Patients Who Have Not Had Success With Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 120
- Registration Number
- NCT00001025
- Locations
- 🇺🇸
SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, United States
🇺🇸Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States
🇺🇸Univ of Alabama at Birmingham, Birmingham, Alabama, United States
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 32
- Registration Number
- NCT00000865
- Locations
- 🇺🇸
UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.